A call has been made for “full transparency” about payments made by drug companies to healthcare professionals and healthcare ...

Through the pharmacoeconomics unit at CAPA, many cost effectiveness and cost utility models have been submitted to the committee, helping to support the case for new interventions.

HSE-funded hospitals are getting large sums of money from big pharmaceutical companies which paid out €32.5m last year to a ...

Expert Rev Pharmacoeconomics Outcomes Res. 2013;13(2):227-235. Importantly, existing data suggest a need for further pharmacoeconomic studies, given the limitations with existing economic studies ...

Pharmacoeconomics plays a role in health-care policy decisions, in comparing and cost-optimizing clinical practice pathways, and in business strategy such as pricing.

The pharmacoeconomics of IBD is a conglomeration of all of these issues, and will probably be a topic of great scrutiny in the years to come. Disease-specific issues for consideration.

This series of pharmacoeconomics posts will explore the meaning of $100,000/quality-adjusted life year (QALY) and why it might matter to these 4 P’s: patients, payers, providers, and pharma.

Leerink has launched the Center for Pharmacoeconomics, which is an effort to quantify the long-term societal impact of healthcare innovations.

International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework Daniel C. Malone , Nancy S. Berg , Karl Claxton , Louis P.

Expert Rev Pharmacoeconomics Outcomes Res. 2013;13(2):227-235. †Included absence of a breakthrough fungal infection, survival for 7 days beyond end of therapy, no premature discontinuation of ...

This series of pharmacoeconomics posts will explore the meaning of $100,000/quality-adjusted life year (QALY) and why it might matter to these 4 P’s: patients, payers, providers, and pharma.